Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,085 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06605521Recruiting
Study on removing lymph nodes above the collarbone for breast cancer
This trial tests if removing cancerous lymph nodes above the collarbone helps treat breast cancer that has spread there. It aims to see if this surgery, along with standard treatments, is safe and effective.
Zhengzhou, HenanAges 18–80 - NCT07657130RecruitingPhase 2
Timing of ADC drug for advanced breast cancer
This trial is testing the best time to give an antibody-drug conjugate (ADC) to people with advanced breast cancer that is HER2-negative. It aims to find out if giving this treatment after first chemotherapy fails can help slow the cancer's growth.
Shenyang, LiaoningAges 18–75 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT06713161Recruiting
New dye to spot breast cancer during surgery
This study tests a special dye that helps surgeons see breast cancer tissue and nearby lymph nodes more clearly during surgery. The goal is to make sure all cancer is removed while sparing healthy tissue.
Kunming, YunnanAges 18–75 - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT06761027RecruitingPhase 1/Phase 2
Three-drug chemo plus targeted and immune therapy for advanced pancreatic cancer
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Fuzhou, FujianAges 18–75 - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07425002Recruiting
Precision Oncology Study in Breast Cancer (PRISM)
This study looks at tumor tissue from people with breast cancer, including those with brain metastases. It aims to learn more about the genetic changes in the cancer to help guide future treatments.
Dublin, LeinsterAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07376538RecruitingPhase 2
Treating advanced breast cancer based on treatment response
This trial tests a personalized approach to treating breast cancer that has spread to nearby lymph nodes. Your surgery and radiation will be tailored to how well your cancer responds to initial chemotherapy or hormone therapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07260591RecruitingPhase 1
VSV-02 for advanced solid tumors that need new options
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
Xinxiang, HenanAges 18 years+ - NCT07224464Recruiting
Sarah Nanotechnology System for advanced solid tumors using heat therapy
This trial tests a new nanotechnology system that uses controlled heat to treat advanced solid tumors in the chest or abdomen that have not responded to standard treatments. It may be an option if you have few remaining choices and want to explore a novel approach.
Rochester, MinnesotaAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT07195513Recruiting
Helping advanced cancer patients connect to palliative care via electronic reporting
This trial uses electronic surveys to identify symptoms and unmet needs in people with advanced cancer, then connects them to palliative care services. It aims to improve quality of life by making sure patients get the extra support they need.
Lebanon, New HampshireAges 18 years+ - NCT07154563Recruiting
Quick test for breast cancer spread to lymph nodes using a new probe
This trial uses a special probe that lights up cancer cells to quickly check if breast cancer has spread to nearby lymph nodes. It may help doctors decide how much surgery is needed.
Kunming, YunnanAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,085 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.